What Neuro-Sys does

Neuro-Sys is a France-headquartered, privately-held contract research organization (CRO) founded in 2013 that delivers specialized in vitro and in vivo preclinical modeling services for neurodegenerative disease drug discovery. Its service portfolio spans disease models across central nervous system conditions (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis, central myelination), peripheral nervous system conditions (induced peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy, BBB penetrance studies). These models are delivered through an integrated multi-platform architecture that includes in vitro, in vivo, histology, electromyography (EMG), analytical chemistry, and biomolecular analysis platforms, supported by a dedicated mode-of-action research line covering pharmacological tools, siRNA studies, and biomolecular investigations.

The company's underlying technology stack combines classical preclinical wet-lab infrastructure with CORTEX AI, an AI-augmented data analysis capability launched in January 2024 intended to improve precision and throughput in mechanism-of-action studies. Operations are anchored at a 2,000 m² state-of-the-art research facility in Gardanne, France (opened September 2024, representing a 4x capacity expansion) and a North American commercial office in Cambridge, Massachusetts (established 2019), under a group structure that includes the operating entity Neuro-Sys SAS, Neuro-Sys Vivo SAS, and Neuro-Sys Inc. Approximately 80% of models delivered are bespoke/customized, 240+ studies were completed in 2024, and the team comprises 40+ specialized experts with 40% holding PhDs.

Neuro-Sys generates revenue on a project-based, quote-driven professional services model, with pricing negotiated per study and not publicly disclosed. Its go-to-market is enterprise field sales, with CEO, CSO, and VP of Business Development personally attending partnering meetings at major industry conferences (BIO, AD/PD, SfN, AAIC, ALS Drug Development Summit). Customers are segmented across large pharmaceutical companies, biotechnology companies, and academic institutions on a horizontal basis, with no named anchor customer logos disclosed in the available data. The company is privately held with no disclosed external funding rounds, was recognized as 'Best Neurodegenerative Disease CRO 2024' by Global Health Pharma, and its parent group (N6-Pharma Group) obtained French 'société à mission' status in June 2025.

Name

Neuro-Sys

Legal name

Neuro-Sys SAS

Website

https://neuro-sys.fr

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Neuro-Sys is a France-based, privately-held preclinical CRO founded in 2013 that provides advanced in vitro and in vivo neurodegenerative disease models (CNS, PNS, and rare diseases) to pharmaceutical, biotech, and academic clients globally from facilities in France and Cambridge, MA.

Ownership category

akta.pro rank

Headquarters

HQ city

Gardanne

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. CRO Contract Research Services: Contract research organization providing preclinical drug discovery services including in vitro and in vivo models, mode of action research, and drug development advisory services on a project basis to pharmaceutical, biotech, and academic clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Neuro-Sys is a research-driven Contract Research Organization (CRO) providing preclinical drug discovery services for neurodegenerative diseases. The company delivers advanced in vitro and in vivo models spanning CNS disorders (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis), PNS conditions (peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy). Services include mode of action research, biomolecular and analytical investigations, and drug development advisory, all supported by proprietary laboratory platforms and the CORTEX AI initiative for AI-powered data analysis.

Product overview

Neuro-Sys is a research-driven contract research organization (CRO) offering specialized preclinical services for neurodegenerative disease drug discovery. The company operates a multi-platform architecture combining in vitro and in vivo testing platforms (including histology, EMG, analytical, and biomolecular analysis capabilities) with disease-specific model portfolios spanning CNS disorders (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis), PNS conditions (peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy). The company also provides mode of action research services and has developed CORTEX AI, an AI-powered data analysis capability for neuroscientific studies. All services are delivered through an integrated drug development advisory platform.

Differentiator

Problem solved

Functional benefit

Products and services

• CNS Disease Models

Quantifiable outcome

• 240+ studies completed in 2024
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered minor.

• Science ExchangeminorOthers · 1 September 2024Neuro-Sys is listed as a service provider on Science Exchange platform, which connects researchers with contract research organizations for scientific studies.
• Scientist.comminorOthers · 1 September 2024Neuro-Sys is a verified supplier on Scientist.com, a marketplace connecting pharma, biotech, and academic organizations with research service providers.
• Biocom CaliforniaminorOthers · 1 September 2024Neuro-Sys is a member of Biocom California, a professional association serving the life science industry in California.
• California Life Sciences Association (CLSA)minorOthers · 1 September 2024Neuro-Sys is a member of CLSA, representing California's life sciences industry.
• Brain Awareness WeekminorOthers · 1 September 2024Neuro-Sys is a proud member/supporter of Brain Awareness Week, a global campaign to increase public awareness of brain research.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• PsychoGenics: US-based preclinical CRO focused on CNS and neurodegenerative disease drug discovery using in vivo and in vitro models. Directly comparable to Neuro-Sys in therapeutic focus, model offerings, and customer base of pharma/biotech CNS programs.
• Crown Bioscience: Global preclinical CRO with neurodegenerative disease and CNS oncology models. Comparable in offering in vivo and in vitro disease models to pharma/biotech sponsors on a contract basis.
• Biotrial (Syneirse): France-based CRO with significant CNS and neurology clinical/preclinical expertise. Comparable geographic roots and CNS therapeutic focus to Neuro-Sys, though with stronger clinical trial capabilities.
• QPS Holdings: Global CRO with strong neuroscience and neurodegenerative disease preclinical capabilities including in vivo models and biomarker work. Comparable therapeutic specialization and CRO service model to Neuro-Sys.
• Sygnature Discovery: UK-based drug discovery CRO with CNS and neurodegenerative disease expertise in preclinical model development. Comparable specialty CRO positioning and therapeutic focus to Neuro-Sys.

Broad incumbents

• Charles River Laboratories: Global tier-1 CRO offering in vivo CNS models, neuropharmacology, and neurodegenerative disease services as part of a much broader portfolio. Comparable services but at vastly larger scale and broader therapeutic coverage.
• WuXi AppTec: Large global CRO/CDMO with preclinical capabilities including neuroscience services. Competes on scale and integrated discovery services but with broader therapeutic area coverage than Neuro-Sys.
• Evotec: Large German CRO with established neuroscience franchise and broad discovery-to-development capabilities. Overlaps with Neuro-Sys in CNS/neurodegenerative preclinical services but operates at significantly larger scale.
• IQVIA: World's largest CRO with preclinical through clinical services including neuroscience capabilities. Competes for outsourced pharma R&D budgets but with vastly broader service portfolio than Neuro-Sys.
• Labcorp Drug Development (formerly Covance): Tier-1 CRO with preclinical CNS and neurodegenerative capabilities alongside full clinical and central lab services. Represents an integrated alternative that Neuro-Sys's prospects may use instead of specialty CROs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neuro-sys
• Xx.com/SYSNEURO

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuro-Sys